Literature DB >> 19473992

Plk1-mediated phosphorylation of Topors regulates p53 stability.

Xiaoming Yang1, Hongchang Li, Zinan Zhou, Wen-Horng Wang, Anping Deng, Ourania Andrisani, Xiaoqi Liu.   

Abstract

Polo-like kinase 1 (Plk1) overexpression is associated with tumorigenesis by an unknown mechanism. Likewise, Plk1 was suggested to act as a negative regulator of tumor suppressor p53, but the mechanism remains to be determined. Herein, we have identified topoisomerase I-binding protein (Topors), a p53-binding protein, as a Plk1 target. We show that Plk1 phosphorylates Topors on Ser(718) in vivo. Significantly, expression of a Plk1-unphosphorylatable Topors mutant (S718A) leads to a dramatic accumulation of p53 through inhibition of p53 degradation. Topors is an ubiquitin and small ubiquitin-like modifier ubiquitin-protein isopeptide ligase (SUMO E3) ligase. Plk1-mediated phosphorylation of Topors inhibits Topors-mediated sumoylation of p53, whereas p53 ubiquitination is enhanced, leading to p53 degradation. These results demonstrate that Plk1 modulates Topors activity in suppressing p53 function and identify a likely mechanism for the tumorigenic potential of Plk1.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19473992      PMCID: PMC2707202          DOI: 10.1074/jbc.C109.001560

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  27 in total

1.  The topoisomerase I-binding RING protein, topors, is associated with promyelocytic leukemia nuclear bodies.

Authors:  Zeshaan A Rasheed; Ahamed Saleem; Yaniv Ravee; Pier Paolo Pandolfi; Eric H Rubin
Journal:  Exp Cell Res       Date:  2002-07-15       Impact factor: 3.905

Review 2.  Ubiquitin and ubiquitin-like modifications of the p53 family.

Authors:  Ian R Watson; Meredith S Irwin
Journal:  Neoplasia       Date:  2006-08       Impact factor: 5.715

3.  Assembly of a polymeric chain of SUMO1 on human topoisomerase I in vitro.

Authors:  Meiluen Yang; Chia-Tse Hsu; Chun-Yuan Ting; Leroy F Liu; Jaulang Hwang
Journal:  J Biol Chem       Date:  2006-01-20       Impact factor: 5.157

4.  A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.

Authors:  Tony S K Mok; Herman Wong; Benny Zee; Kwok Hung Yu; Thomas W T Leung; Tak Wai Lee; Anthony Yim; Anthony T C Chan; Winnie Yeo; Karen Chak; Philip Johnson
Journal:  Cancer       Date:  2002-10-01       Impact factor: 6.860

5.  Identification of phosphorylation sites of TOPORS and a role for serine 98 in the regulation of ubiquitin but not SUMO E3 ligase activity.

Authors:  Hye-Jin Park; Haiyan Zheng; Diptee Kulkarni; John Kerrigan; Pooja Pungaliya; Ahamed Saleem; Eric H Rubin
Journal:  Biochemistry       Date:  2008-12-30       Impact factor: 3.162

6.  Plk1 phosphorylation of TRF1 is essential for its binding to telomeres.

Authors:  Zhao-Qiu Wu; Xiaoming Yang; Gregory Weber; Xiaoqi Liu
Journal:  J Biol Chem       Date:  2008-07-14       Impact factor: 5.157

7.  Ubiquitination by TOPORS regulates the prostate tumor suppressor NKX3.1.

Authors:  Bin Guan; Pooja Pungaliya; Xiang Li; Carlos Uquillas; Laura N Mutton; Eric H Rubin; Charles J Bieberich
Journal:  J Biol Chem       Date:  2007-12-12       Impact factor: 5.157

8.  Modification of Drosophila p53 by SUMO modulates its transactivation and pro-apoptotic functions.

Authors:  Federico Mauri; Laura M McNamee; Andrea Lunardi; Fulvio Chiacchiera; Giannino Del Sal; Michael H Brodsky; Licio Collavin
Journal:  J Biol Chem       Date:  2008-05-20       Impact factor: 5.157

9.  Gene expression patterns in human liver cancers.

Authors:  Xin Chen; Siu Tim Cheung; Samuel So; Sheung Tat Fan; Christopher Barry; John Higgins; Kin-Man Lai; Jiafu Ji; Sandrine Dudoit; Irene O L Ng; Matt Van De Rijn; David Botstein; Patrick O Brown
Journal:  Mol Biol Cell       Date:  2002-06       Impact factor: 4.138

10.  Role for Plk1 phosphorylation of Hbo1 in regulation of replication licensing.

Authors:  Zhao-Qiu Wu; Xiaoqi Liu
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-04       Impact factor: 11.205

View more
  52 in total

1.  Inhibition of Polo-like kinase 1 prevents the growth of metastatic breast cancer cells in the brain.

Authors:  Yongzhen Qian; Emily Hua; Kheem Bisht; Stephan Woditschka; Konstantine W Skordos; David J Liewehr; Seth M Steinberg; Edi Brogi; Muzaffar M Akram; J Keith Killian; Daniel C Edelman; Marbin Pineda; Stephanie Scurci; Yan Y Degenhardt; Sylvie Laquerre; Thomas A Lampkin; Paul S Meltzer; Kevin Camphausen; Patricia S Steeg; Diane Palmieri
Journal:  Clin Exp Metastasis       Date:  2011-09-21       Impact factor: 5.150

2.  Numb regulates stability and localization of the mitotic kinase PLK1 and is required for transit through mitosis.

Authors:  Travis L Schmit; Minakshi Nihal; Mary Ndiaye; Vijayasaradhi Setaluri; Vladimir S Spiegelman; Nihal Ahmad
Journal:  Cancer Res       Date:  2012-05-16       Impact factor: 12.701

Review 3.  SUMO rules: regulatory concepts and their implication in neurologic functions.

Authors:  Mathias Droescher; Viduth K Chaugule; Andrea Pichler
Journal:  Neuromolecular Med       Date:  2013-08-30       Impact factor: 3.843

4.  Combining p53 stabilizers with metformin induces synergistic apoptosis through regulation of energy metabolism in castration-resistant prostate cancer.

Authors:  Long Chen; Nihal Ahmad; Xiaoqi Liu
Journal:  Cell Cycle       Date:  2016       Impact factor: 4.534

Review 5.  Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy.

Authors:  Klaus Strebhardt
Journal:  Nat Rev Drug Discov       Date:  2010-08       Impact factor: 84.694

Review 6.  Polo-like kinase 1, on the rise from cell cycle regulation to prostate cancer development.

Authors:  Jijing Luo; Xiaoqi Liu
Journal:  Protein Cell       Date:  2012-03-23       Impact factor: 14.870

7.  Polo-like kinase 1 activated by the hepatitis B virus X protein attenuates both the DNA damage checkpoint and DNA repair resulting in partial polyploidy.

Authors:  Leo Studach; Wen-Horng Wang; Gregory Weber; Jiabin Tang; Ronald L Hullinger; Raphael Malbrue; Xiaoqi Liu; Ourania Andrisani
Journal:  J Biol Chem       Date:  2010-07-12       Impact factor: 5.157

8.  Plk1 inhibition enhances the efficacy of androgen signaling blockade in castration-resistant prostate cancer.

Authors:  Zhe Zhang; Xianzeng Hou; Chen Shao; Junjie Li; Ji-Xin Cheng; Shihuan Kuang; Nihal Ahmad; Timothy Ratliff; Xiaoqi Liu
Journal:  Cancer Res       Date:  2014-09-24       Impact factor: 12.701

9.  Plk1-Mediated Phosphorylation of TSC1 Enhances the Efficacy of Rapamycin.

Authors:  Zhiguo Li; Yifan Kong; Longzhen Song; Qian Luo; Jinghui Liu; Chen Shao; Xianzeng Hou; Xiaoqi Liu
Journal:  Cancer Res       Date:  2018-03-20       Impact factor: 12.701

10.  Polo-like kinase 1 (Plk1) overexpression enhances ionizing radiation-induced cancer formation in mice.

Authors:  Zhiguo Li; Jinghui Liu; Jie Li; Yifan Kong; George Sandusky; Xi Rao; Yunlong Liu; Jun Wan; Xiaoqi Liu
Journal:  J Biol Chem       Date:  2017-09-12       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.